Eli Lilly Stock Is Rising Monday: What's Going On?
Eli Lilly Stock Is Rising Monday: What's Going On?
"Today, many cases of OSA go undiagnosed and untreated, leaving millions at risk for serious health consequences," said Eli Lilly and Company (NYSE:LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA approved the company's Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
礼来公司（纽交所：LLY）股票在周一交易中上涨。股价的上涨势头是因为FDA批准了该公司的Zepbound，这是一种用于治疗肥胖成年人中度至重度 obstructive sleep apnea 的减重药物。
What To Know: After the market close on Friday, Eli Lilly announced FDA approval of Zepbound (tirzepatide) as the first prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity.
重要信息：在周五市场收盘后，礼来宣布Zepbound（tirzepatide）获得FDA批准，成为首个用于治疗中度至重度 obstructive sleep apnea 和肥胖的处方药。
Obstructive sleep apnea is estimated to affect 50 million to 80 million people in the U.S., with an estimated 20 million suffering from moderate-to-severe forms. Clinical trials demonstrated the drug's efficacy, with nearly half of patients on the highest dose showing significant improvement in their apnea-hypopnea index, a primary diagnostic metric.
据了解，阻塞性睡眠呼吸暂停在美国影响约5000万至8000万的人，估计有2000万人患有中度至重度的形式。临床试验显示，该药物有效，近一半在最高剂量下的患者在其apnea-hypopnea指数上显示出显著改善，这是一个主要的诊断指标。
"Today, many cases of OSA go undiagnosed and untreated, leaving millions at risk for serious health consequences," said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA. "Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity."
礼来心血管代谢健康及礼来美国总裁Patrik Jonsson表示：“如今，许多阻塞性睡眠呼吸暂停的案例未被诊断和治疗，使得数百万人面临严重的健康风险。Zepbound是第一种显著改善中度至重度阻塞性睡眠呼吸暂停并帮助肥胖成年人长期减重的药物。”
The approval is expected to impact insurance coverage for Zepbound, potentially expanding Medicare benefits for obesity-related treatments. In addition to improved obstructive sleep apnea symptoms, adults on Zepbound lost an average of 45 lbs (18%) of their body weight in Phase 3 trials.
这一批准预计将影响Zepbound的保险覆盖，可能扩展医疗保险对肥胖相关治疗的福利。根据第3期试验，服用Zepbound的成年人平均减重45磅（18%）。
The approval also positions Eli Lilly ahead of competitors like Novo Nordisk, whose Wegovy lacks approval for sleep apnea. The company's ongoing $3 billion investment in manufacturing capacity underscores its focus on meeting demand for its diabetes and obesity treatments.
这一批准也使得礼来在竞争对手如诺和诺德（Novo Nordisk）之前走在了前面，其Wegovy尚未获得睡眠呼吸暂停的批准。该公司正在进行30亿的制造能力投资，显示其致力于满足糖尿病和肥胖治疗的需求。
Eli Lilly reported third-quarter revenue of $11.44 billion in October, reflecting a 20% year-over-year increase. Zepbound accounted for approximately $1.26 billion in total revenue during the quarter.
礼来在10月份报告了第三季度营业收入为114.4亿美元，同比增长20%。在这一季度，Zepbound贡献了约12.6亿美元的总收入。
LLY Price Action: Eli Lilly shares were up 3.11% at $791.63 at the time of writing, according to Benzinga Pro.
LLY股价动态：根据Benzinga Pro，礼来股票在撰写时上涨了3.11%，目前价格为791.63美元。
- Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
- 辉瑞在C. diff生物-疫苗和肺炎球菌疫苗上的进展赢得了分析师的信心。
Image Via Shutterstock.
图片来自Shutterstock。
